Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 9:12:1096717.
doi: 10.3389/fonc.2022.1096717. eCollection 2022.

Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment

Rongyang Li  1 , Bing Huang  1 , Hui Tian  1 , Zhenguo Sun  1
Affiliations
Review

Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment

Rongyang Li et al. Front Oncol. .

Abstract

Esophageal cancer (EC) is one of the most life-threatening malignancies worldwide. Esophageal squamous cell carcinoma (ESCC) is the dominant subtype, accounting for approximately 90% of new incident EC each year. Although multidisciplinary treatment strategies have advanced rapidly, patients with ESCC are often diagnosed at advanced stage and the long-term prognosis remains unsatisfactory. In recent decades, immunotherapy, such as immune checkpoint inhibitors (ICIs), tumor vaccines, and chimeric antigen receptor T-cell (CAR-T) therapy, has been successfully used in clinical practice as a novel therapy for treating tumors, bringing new hope to ESCC patients. However, only a small fraction of patients achieved clinical benefits due to primary or acquired resistance. Immune evasion plays a pivotal role in the initiation and progression of ESCC. Therefore, a thorough understanding of the mechanisms by which ESCC cells escape from anti-tumor immunity is necessary for a more effective multidisciplinary treatment strategy. It has been widely recognized that immune evasion is closely associated with the crosstalk between tumor cells and the tumor microenvironment (TME). TME is a dynamic complex and comprehensive system including not only cellular components but also non-cellular components, which influence hallmarks and fates of tumor cells from the outside. Novel immunotherapy targeting tumor-favorable TME represents a promising strategy to achieve better therapeutic responses for patients with ESCC. In this review, we provide an overview of immune evasion in ESCC, mainly focusing on the molecular mechanisms that underlie the role of TME in immune evasion of ESCC. In addition, we also discuss the challenges and opportunities of precision therapy for ESCC by targeting TME.

Keywords: esophageal squamous cell cancer; immune evasion; immunosuppression; immunotherapy; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Immunosuppressive tumor microenvironment (TME) in esophageal squamous cell cancer (ESCC). TME is a dynamic complex and comprehensive system, composed of various cellular components and non-cellular components. ESCC cells are born to create an immunosuppressive milieu suppressing the proliferation and function of cytolytic NK and T cells directly and indirectly. ESCC, esophageal squamous cell cancer; CTL, cytotoxic T lymphocyte; NK, natural killer cell; MDSC, myeloid-derived suppressor cell; TAM, tumor-associated macrophage; CAF, cancer-associated fibroblast; Treg, regulator T cell; TAN, tumor-associated neutrophils; Th17, T helper cell 17; MHC-1, major histocompatibility class I; TCR, T cell receptor; KAR, killer activation receptor; KIR, killer inhibitory receptor; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; LAG-3, lymphocyte activation gene-3; TIM-3, T-cell immunoglobulin and mucin domain-containing protein-3; TIGIT, T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain; TGF-β, transforming growth factor-β; IL, interleukin; CXCL, CXC motif chemokine ligand; CCL, CC motif chemokine ligand; CCR, CC motif chemokine receptor; IDO, indoleamine 2,3-dioxygenase; iNOS, inducible nitric oxide synthase-2; ROS, reactive oxygen species.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. . Cancer statistics in China and united states, 2022: profiles, trends, and determinants. Chin Med J (2022) 135(5):584–90. doi: 10.1097/CM9.0000000000002108 - DOI - PMC - PubMed
    1. Lagergren J, Lagergren P. Oesophageal cancer. BMJ (Clinical Res ed) (2010) 341:c6280. doi: 10.1136/bmj.c6280 - DOI - PubMed
    1. Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J gastroenterology. (2015) 21(26):7933–43. doi: 10.3748/wjg.v21.i26.7933 - DOI - PMC - PubMed
    1. Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet (London England). (2017) 390(10110):2383–96. doi: 10.1016/S0140-6736(17)31462-9 - DOI - PubMed

Grants and funding

This work was funded by the National Key R&D Program of China (2021YFC2500900, 2021YFC2500904 and 2021YFC2500905), National Natural Science Foundation of China (81802397), China Postdoctoral Science Foundation (2020M672073), and Shandong Provincial Natural Science Foundation (ZR2017BH035).

LinkOut - more resources